Mammalian target of rapamycin as a therapeutic target in osteoporosis

Area of Science:

• Cell Biology
• Biochemistry
• Orthopedics

Background:

• The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth, metabolism, and homeostasis.
• Emerging evidence implicates mTOR signaling in the maintenance of bone health and the pathogenesis of osteoporosis.
• mTOR's role in modulating key cellular processes within bone tissue is increasingly recognized.

Purpose of the Study:

• To elucidate the intricate mechanisms by which mTOR signaling influences bone homeostasis.
• To explore the association between mTOR pathway dysregulation and the development of osteoporosis.
• To discuss the therapeutic potential of targeting mTOR in osteoporosis treatment.

Main Methods:

• Review of current literature on mTOR signaling and bone biology.
• Analysis of studies investigating mTOR's impact on bone marrow mesenchymal stem cells (BMSCs), osteoblasts, osteocytes, and osteoclasts.
• Integration of findings related to mTOR activation/inhibition and bone cell function.

Main Results:

• mTOR signaling positively regulates osteoblast differentiation and bone formation.
• mTOR signaling negatively impacts osteoclast differentiation and bone resorption.
• Aberrant mTOR activity in BMSCs affects their differentiation potential, contributing to altered bone homeostasis.
• mTOR pathway modulation influences osteocyte survival and function.

Conclusions:

• The mTOR pathway is a critical regulator of bone homeostasis, influencing both bone formation and resorption.
• Dysregulation of mTOR signaling is implicated in the pathogenesis of osteoporosis.
• Targeting the mTOR pathway presents a promising therapeutic avenue for managing osteoporosis.